GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has recently secured approximately $27 million in international orders targeted for delivery in 2025 associated with its medical countermeasures (MCM) portfolio. These orders will help address potential threats of smallpox and anthrax and will contribute to the overall supply of MCM’s to the international market in 2025.
“Emergent is a trusted partner to supply communities around the world with medical countermeasures that protect against serious health threats like smallpox and anthrax,” said Joe Papa, president and CEO of Emergent. “We are pleased to engage and support global partners in fulfilling their preparedness needs. As part of our multi-year transformation plan, we will continue to focus on international expansion efforts and strengthening health preparedness at home and abroad.”
Emergent specializes in developing, manufacturing, and supplying MCMs for national security and public health preparedness. These products enable governments to effectively respond to emergencies and protect the public from potential threats. The types and quantities of products that should be maintained in a stockpile will depend on the population requiring protection, the products available for meeting the threat, as well as government resources and priorities.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Assal Hellmer
Vice President, Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.62 |
| Daily Volume: | 593,110 |
| Market Cap: | US$250.310M |
March 20, 2025 January 16, 2025 January 14, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
